Calidi Biotherapeutics (CLDI) Competitors $0.25 +0.01 (+5.60%) Closing price 07/3/2025 03:49 PM EasternExtended Trading$0.25 0.00 (0.00%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDI vs. VOR, EGRX, AKTX, ELYM, ESLA, XLO, LVTX, LTRN, SCLX, and RNTXShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Vor Biopharma (VOR), Eagle Pharmaceuticals (EGRX), Akari Therapeutics (AKTX), Eliem Therapeutics (ELYM), Estrella Immunopharma (ESLA), Xilio Therapeutics (XLO), LAVA Therapeutics (LVTX), Lantern Pharma (LTRN), Scilex (SCLX), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. Its Competitors Vor Biopharma Eagle Pharmaceuticals Akari Therapeutics Eliem Therapeutics Estrella Immunopharma Xilio Therapeutics LAVA Therapeutics Lantern Pharma Scilex Rein Therapeutics Calidi Biotherapeutics (NYSE:CLDI) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership. Do insiders & institutionals hold more shares of CLDI or VOR? 12.5% of Calidi Biotherapeutics shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 6.7% of Calidi Biotherapeutics shares are held by company insiders. Comparatively, 2.9% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, CLDI or VOR? Calidi Biotherapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Does the media favor CLDI or VOR? In the previous week, Vor Biopharma had 11 more articles in the media than Calidi Biotherapeutics. MarketBeat recorded 11 mentions for Vor Biopharma and 0 mentions for Calidi Biotherapeutics. Vor Biopharma's average media sentiment score of 0.28 beat Calidi Biotherapeutics' score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Calidi Biotherapeutics Neutral Vor Biopharma Neutral Is CLDI or VOR more profitable? Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% Vor Biopharma N/A N/A N/A Do analysts prefer CLDI or VOR? Vor Biopharma has a consensus target price of $5.63, suggesting a potential upside of 198.60%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Calidi Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vor Biopharma 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has better earnings and valuation, CLDI or VOR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi BiotherapeuticsN/AN/A-$29.22MN/AN/AVor BiopharmaN/AN/AN/A-$1.51-1.25 SummaryVor Biopharma beats Calidi Biotherapeutics on 8 of the 9 factors compared between the two stocks. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLDI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$7.85M$202.67M$5.53B$20.73BDividend YieldN/AN/A5.24%3.72%P/E RatioN/AN/A27.5228.09Price / SalesN/A223.65421.0238.31Price / CashN/A22.4436.8922.53Price / Book-0.115.618.044.58Net Income-$29.22M-$96.61M$3.18B$986.06M7 Day Performance10.42%-0.74%2.90%2.79%1 Month Performance-30.73%-1.17%3.70%5.46%1 Year Performance-87.55%10.52%36.15%15.06% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics0.2173 of 5 stars$0.25+5.6%N/AN/A$7.85MN/A0.0038VORVor Biopharma3.9894 of 5 stars$0.29+20.7%$7.06+2,333.5%+104.9%$36.24MN/A-0.18140Analyst RevisionGap UpHigh Trading VolumeEGRXEagle PharmaceuticalsN/A$2.79-3.0%N/A-45.5%$36.23M$257.55M0.00100Gap DownAKTXAkari Therapeutics1.5648 of 5 stars$1.16+3.6%N/A-62.9%$36.04MN/A0.009ELYMEliem TherapeuticsN/A$1.21-1.6%N/A-81.3%$36MN/A-2.289ESLAEstrella Immunopharma2.2338 of 5 stars$0.92-7.1%$16.00+1,639.1%-19.3%$35.80MN/A-3.54N/AGap UpXLOXilio Therapeutics2.7517 of 5 stars$0.67-2.7%$4.00+497.0%-19.7%$35.65M$6.34M-0.8070News CoveragePositive NewsLVTXLAVA Therapeutics1.8368 of 5 stars$1.33+1.1%$3.17+139.0%-25.8%$34.46M$11.98M-1.2760LTRNLantern Pharma2.481 of 5 stars$3.07-3.5%$25.00+714.3%-25.9%$34.30MN/A-1.6720News CoverageGap DownSCLXScilex1.743 of 5 stars$4.98+1.4%$455.00+9,036.5%-90.5%$34.13M$56.59M-0.1780RNTXRein TherapeuticsN/A$1.50-2.6%N/AN/A$34.12MN/A-0.529Gap Up Related Companies and Tools Related Companies Vor Biopharma Competitors Eagle Pharmaceuticals Competitors Akari Therapeutics Competitors Eliem Therapeutics Competitors Estrella Immunopharma Competitors Xilio Therapeutics Competitors LAVA Therapeutics Competitors Lantern Pharma Competitors Scilex Competitors Rein Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CLDI) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDI Stock Alerts